LL2-00 digest: Acknowledgements, Preface, Ch1 Introduction, Part A introduction#

Late lessons from early warnings: science, precaution, innovation (EEA 2013). Report pp. 1–16 (PDF pp. 3–18). Full notes: notes/LL2-00.md.

Core argument#

Vol 2’s thesis is that the relationship between knowledge and power decides when societies act on early warnings (p. 7).

• Preface (Jacqueline McGlade, EEA Executive Director, pp. 6–8). An openly normative essay, opening “There is something profoundly wrong with the way we are living today” (p. 6).
• It links environmental-health failures to inequality, the “hubris” of the 2007–2009 financial crisis, and collapsing trust (p. 6).
• It says scientific elites are losing support partly through “misplaced certainty about the absence of harm” (p. 6).
• It argues chemicals regimes act through “the main economic actors rather than communities or individuals” (p. 7).
• It calls for “the power structures of knowledge” to change (p. 8).
• Introduction (unsigned, pp. 9–11). Gives four reasons for Vol 2: more cases; false positives; emerging technologies; systemic challenges (p. 9). It then summarises each Part’s conclusions.

Key claims#

These summarise later chapters; the evidence is not shown here.

• False positives are “few and far between as compared to false negatives”, and careful precaution can stimulate innovation (p. 10). This rests on Ch 2: 88 alleged, 4 confirmed (p. 17). The preface loosely says “80 or so” potential cases (p. 8).
• Nine Part A false negatives (lead, PCE, Minamata, beryllium, second-hand smoke, vinyl chloride, DBCP, BPA, DDT) yield three common themes: “more than sufficient evidence for much earlier action”; “slow and sometimes obstructive behaviour by businesses”; and the value of independent science (p. 10).
• Societies are “by and large” not using historical lessons. Delay stems from novelty, poorly evaluated information, opposition by “corporate and scientific establishments”, and status-quo, short-term institutions (pp. 10–11).
• Harms were “for the most part” caused by “irresponsible corporations”, compounded by government decision practices and the law’s shortcomings in compensating victims (p. 11). The preface also blames citizens protecting “assets accumulated in easier times” (p. 6).
• Persistent chemicals bioaccumulate, and small doses in developmental windows can be “devastating” (p. 7).
• Vol 1’s twelve lessons “remain highly pertinent” (pp. 9, 11). They are mostly procedural, ending with: avoid “paralysis by analysis” when there are “reasonable grounds for concern”.

Transferable insights (technology-neutral)#

1. Distinguish deciding under uncertainty from failing to act on strong evidence. Many lessons are the latter (pp. 9–10). Moderate.
2. How knowledge is funded and produced is a site of power, commercial and “paradigmatic” (pp. 7, 10). Asserted here.
3. Confident “no harm” claims held “despite evidence to the contrary” are a recurrent failure (p. 6). Asserted. The trust-erosion mechanism is unevidenced.
4. Deployment that outpaces knowledge lets exposure accumulate first: “largely unknown, yet already widespread” (p. 10). Asserted.
5. Persistence and vulnerable-window exposure make delay costly and long-lasting. Averages may hide those most at risk (pp. 7–8). Moderate.
6. Delay has recurring causes, including incumbent scientific as well as corporate opposition (pp. 10–11). Moderate. The cases were selected as failures.
7. Some producers delay or obstruct action and manufacture doubt, sometimes shaping the assessment rules themselves (p. 10; panel 7.1, p. 16). Asserted here. The “for the most part” generalisation (p. 11) goes beyond what this section shows; state actors also appear (for example the US DOE on beryllium, p. 145).
8. Independent research and regulators matter; the same data can yield different assessments (p. 10; lesson 10; panel 4.1). Moderate.
9. The false-alarm objection is weaker than claimed (p. 10). Suggestive. It rests on one chapter’s classification (led by editor Hansen, with Tickner), with no common denominator for the comparison.
10. Precaution can drive innovation via substitution and alternatives (pp. 7, 10–11; lesson 7). Suggestive.
11. Cost estimates for action and inaction can be “skewed”, and remedies for those harmed are weak; top-down regimes miss local harms and knowledge (pp. 7–8, 10–11). Asserted/suggestive.
12. History yields “insight”, not rules (Collingwood, p. 7). This is the report’s own method, and a limit on how mechanically lessons should be applied.

Standpoint and caveats#

• Case and author selection. Case advice came from the editor, editorial team, advisory board, EEA Scientific Committee and the Collegium Ramazzini, whose stated mission includes bridging science to those who “must act… to protect public health” (p. 9). Authors were chosen for “substantial involvement” (pp. 9–10).
• Authors as protagonists. Annex 1 shows many were protagonists: Needleman on lead; Michaels, then head of OSHA, formerly the DOE assistant secretary for worker health at nuclear weapons sites, and a former beryllium expert witness; Bingham, a former OSHA head; an NRDC advocate; Minamata court witnesses.
• Editors as authors. Editors wrote or led the false-positives chapter and the signed concluding chapters (Ch 26, 27); Ch 28 is unsigned.
• Missing voices. Judging by affiliation, no Part A panel or commentary comes from a company whose conduct is at issue, or from a regulator defending itself. Four commentaries are left off the panel list (p. 16). They include Guidotti’s on beryllium (p. 145), which reads corporate motive as “denial rather than cupidity” and notes that the US DOE “abetted” the company, and Castaño’s on fish (p. 130), which warns against exaggerating risk.
• Opaque process. Reviewers are unnamed, and the “seven structuring questions” are not given in this section (p. 10).
• Hindsight. “Sufficient evidence” is judged with hindsight, and no prospective criteria for credible warnings are given.
• Slips. BPA is “contested” on p. 8 but a “false negative” on p. 10; Vol 1 is misdated “1986–2000” on p. 11; the back-matter page numbers on p. 4 are 30 pages too high from Annex 1 onwards (Annex 1 is actually pp. 685–700).
• Tension. The preface says questions should be framed around which decisions to delegate to experts (p. 8), while also calling for the power structures of knowledge to change.
• Fairness. The report is open about its values and tests false positives, and its core lessons are moderate. It also names causes of delay that involve no bad faith (novelty; poorly evaluated information, pp. 10–11).

Later evidence#

• Trust in scientists. Cologna et al. (2025; 68 countries) find “no widespread lack of trust in scientists”. This does not test a decline over time.
• Number of chemicals. Wang et al. (2020) count over 350,000 registered chemicals and mixtures, not 100,000.
• Rotterdam Convention. Annex III has grown from 39 chemicals (24 + 4 + 11, p. 7) to 57 (pic.int, latest additions in force 22 October 2025).
• BPA. EFSA (2023) cut the tolerable daily intake about 20,000-fold, though other assessors dispute the scale.